[go: up one dir, main page]

PT1087993E - Péptidos fas e anticorpos para modular a apoptose - Google Patents

Péptidos fas e anticorpos para modular a apoptose Download PDF

Info

Publication number
PT1087993E
PT1087993E PT99931070T PT99931070T PT1087993E PT 1087993 E PT1087993 E PT 1087993E PT 99931070 T PT99931070 T PT 99931070T PT 99931070 T PT99931070 T PT 99931070T PT 1087993 E PT1087993 E PT 1087993E
Authority
PT
Portugal
Prior art keywords
antibodies
fas
peptides
modulating apoptosis
cellular proliferation
Prior art date
Application number
PT99931070T
Other languages
English (en)
Inventor
Francesca Chiodi
Original Assignee
Imed Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9813194.9A external-priority patent/GB9813194D0/en
Priority claimed from GBGB9905793.7A external-priority patent/GB9905793D0/en
Application filed by Imed Ab filed Critical Imed Ab
Publication of PT1087993E publication Critical patent/PT1087993E/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4747Apoptosis related proteins
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/30Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/30Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PT99931070T 1998-06-18 1999-06-15 Péptidos fas e anticorpos para modular a apoptose PT1087993E (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9813194.9A GB9813194D0 (en) 1998-06-18 1998-06-18 Methods and means for modulating apoptosis
GBGB9905793.7A GB9905793D0 (en) 1998-06-18 1999-03-12 Methods and means for modulating apoptosis

Publications (1)

Publication Number Publication Date
PT1087993E true PT1087993E (pt) 2008-07-04

Family

ID=26313898

Family Applications (1)

Application Number Title Priority Date Filing Date
PT99931070T PT1087993E (pt) 1998-06-18 1999-06-15 Péptidos fas e anticorpos para modular a apoptose

Country Status (9)

Country Link
US (1) US6846637B1 (pt)
EP (1) EP1087993B1 (pt)
AT (1) ATE391136T1 (pt)
AU (1) AU4772299A (pt)
DE (1) DE69938451T2 (pt)
DK (1) DK1087993T3 (pt)
ES (1) ES2306515T3 (pt)
PT (1) PT1087993E (pt)
WO (1) WO1999065935A2 (pt)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4405916B2 (ja) 2002-05-23 2010-01-27 トラスティース・オブ・ザ・ユニバーシティ・オブ・ペンシルバニア Fasペプチド模倣体およびその使用
AU2003249533A1 (en) 2002-07-04 2004-01-23 Oncomab Gmbh Neoplasm specific antibodies and uses thereof
DE10311248A1 (de) 2003-03-14 2004-09-30 Müller-Hermelink, Hans Konrad, Prof. Dr. Humaner monoklonaler Antikörper
CA2522700A1 (en) * 2003-04-18 2004-11-04 Cytovia, Inc. Methods of treating diseases responsive to induction of apoptosis and screening assays
WO2005094159A2 (en) * 2003-11-12 2005-10-13 Oncomab Gmbh Methods of identifying neoplasm-specific antibodies and uses thereof
DE10353175A1 (de) 2003-11-14 2005-06-16 Müller-Hermelink, Hans Konrad, Prof. Dr. Humaner monoklonaler Antikörper mit fettsenkender Wirkung
EP1531162A1 (en) 2003-11-14 2005-05-18 Heinz Vollmers Adenocarcinoma specific antibody SAM-6, and uses thereof
US7759077B2 (en) 2005-08-02 2010-07-20 Shariat Shahrokh F Soluble fas urinary marker for the detection of bladder transitional cell carcinoma
EP2101877B1 (en) 2006-12-28 2013-06-19 Deutsches Krebsforschungszentrum, Stiftung des öffentlichen Rechts Neutralization of cd95 activity blocks invasion of glioblastoma cells in vivo
US20110189194A1 (en) * 2008-07-14 2011-08-04 Deutsches Krebsforschungszentrum Stiftung Des Offentlichen Rechts Use of cd95 inhibitors for the treatment of inflammatory disorders
WO2010102792A2 (en) * 2009-03-12 2010-09-16 Imed Ab Human antibodies against human fas and their use
JP6297552B2 (ja) 2012-07-18 2018-03-20 アポジェニックス アーゲー Mdsの治療のための、cd95シグナル伝達経路阻害剤
CA2927309A1 (en) 2013-05-24 2014-11-27 Promis Neurosciences Inc. Fasr antibodies for diagnostic and therapeutic use
EP2898896A1 (en) 2014-01-22 2015-07-29 Université Pierre et Marie Curie (Paris 6) Agents for use in the treatment of retinal inflammation
ES2796857T3 (es) * 2014-04-17 2020-11-30 Inst Nat Sante Rech Med Polipéptidos y usos de los mismos para reducir la motilidad celular mediada por CD95
EP3076179A1 (en) 2015-03-30 2016-10-05 Deutsches Krebsforschungszentrum Stiftung des Öffentlichen Rechts Diagnosis and treatment of low grade gliomas
JP7537074B2 (ja) 2016-05-10 2024-08-21 ソルボンヌ ウニベルシテ Cd47を活性化する作用物質およびその炎症治療における使用
BR112021019328A2 (pt) 2019-03-29 2021-11-30 Myst Therapeutics Llc Métodos ex vivo para produzir um produto terapêutico de célula t e composições e métodos relacionados
IL293350A (en) 2019-11-27 2022-07-01 Myst Therapeutics Llc Method of producing tumor-reactive t cell composition using modulatory agents
EP4512828A2 (en) 2020-02-27 2025-02-26 Turnstone Biologics Corp. Methods for ex vivo enrichment and expansion of tumor reactive t cells and related compositions thereof

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69009497T2 (de) 1990-01-19 1994-11-24 German Cancer Research Center, 6900 Heidelberg Mit zellularer apoptosis assoziiertes zelloberflächenantigen.
DE69233441T2 (de) 1991-04-26 2005-10-13 Osaka Bioscience Institute, Suita Menschliches Zelloberflächen-Antigen codierende DNA
US5891434A (en) 1991-06-17 1999-04-06 Centocor, Inc. Monoclonal antibodies to the APO-1 antigen
KR960704938A (ko) 1993-10-14 1996-10-09 그리스토퍼 엘. 와이트 Fas 길항제 및 그의 용도(Fas Antagonists and Uses Thereof)
US5830469A (en) 1993-10-14 1998-11-03 Immunex Corporation Fas antagonists and uses thereof
US5663070A (en) 1993-11-15 1997-09-02 Lxr Biotechnology Inc. Recombinant production of a soluble splice variant of the Fas (Apo-1) antigen, fas TM
CA2158822C (en) 1994-09-27 2008-12-23 Kusuki Nishioka Therapeutic agent for rheumatic disease
JPH08157500A (ja) 1994-12-08 1996-06-18 Oriental Yeast Co Ltd Fas抗原の定量法
WO1997012632A1 (en) 1995-10-05 1997-04-10 Tkb Associates Limited Partnership Methods for treatment of diseases associated with a deficiency of fas ligand activity
DE19544332C2 (de) 1995-11-28 1999-07-08 Deutsches Krebsforsch Verfahren zum Nachweis der Expression von CD95 Ligand in Zellen
JP3663243B2 (ja) 1995-12-14 2005-06-22 株式会社医学生物学研究所 Fas抗原の免疫学的測定法及び測定用キット
NO971448L (no) 1996-04-01 1997-10-02 Sankyo Co Rekombinante anti-Fas-antistoffer og DNA for disse
US5912168A (en) 1996-08-30 1999-06-15 Genesis Research & Development Corporation Limited CD95 regulatory gene sequences
ZA982371B (en) * 1997-03-21 1998-09-28 Sankyo Co Humanized anti-human fas antibody
IL123888A0 (en) 1997-04-01 1998-10-30 Sankyo Co Anti-fas antibodies
AU757961B2 (en) 1998-09-30 2003-03-13 Sankyo Company Limited Anti-Fas antibodies
HUP0201333A3 (en) 1999-05-24 2004-11-29 Sankyo Company Ltd Chuo Ku Medicinal compositions containing anti-fas antibody

Also Published As

Publication number Publication date
WO1999065935A3 (en) 2003-04-17
EP1087993A1 (en) 2001-04-04
AU4772299A (en) 2000-01-05
ES2306515T3 (es) 2008-11-01
DE69938451D1 (de) 2008-05-15
ATE391136T1 (de) 2008-04-15
US6846637B1 (en) 2005-01-25
WO1999065935A2 (en) 1999-12-23
EP1087993B1 (en) 2008-04-02
DE69938451T2 (de) 2009-04-09
DK1087993T3 (da) 2008-07-14

Similar Documents

Publication Publication Date Title
PT1087993E (pt) Péptidos fas e anticorpos para modular a apoptose
NZ332598A (en) Human BAS-1 protein, and use as an antagonist for modulating physiology or development of a cell
WO2003048337A3 (en) Antibody to latent membrane proteins and uses thereof
MY157382A (en) Cripto blocking antibodies and uses thereof.
IL130036A0 (en) Survivin a protein that inhibits cellular apoptosis and its modulation
MXPA04002808A (es) Acidos nucleicos receptores de ecdisona de mosca blanca, polipeptidos, y sus usos.
IL180967A0 (en) Human toll homologues
WO2001081415A3 (en) Parathyroid hormone and parathyroid hormone-related protein antagonists
AU2002323120A1 (en) Periostin-based diagnostic assays
WO2000001813A3 (en) Peptide inhibitors of androgen-independent activation of androgen receptor
EP1517144A3 (en) Method of identifying an antibody binding to and modulating the activity of a human vanilloid receptor
IL134011A0 (en) Adipocyte-specific protein homologs
MXPA02011002A (es) Oligopeptidos para promover el crecimiento del cabello.
ATE513040T1 (de) Zinkfingerdomänenbibliotheken
WO1999033981A3 (en) Human signal peptide-containing proteins
IL149416A0 (en) Human enzymes of the metalloprotease family
ATE240349T1 (de) Peptide zur inhibierung von hpv e6-proteinen
WO2002092765A3 (en) Novel telomerase inhibitors and uses therefor
WO2001016181A3 (en) Crystal structures of domains of receptor protein tyrosine kinases and their ligands
WO2000023589A3 (en) Proliferation and apoptosis related proteins
BR0207253A (pt) Polinucleotìdeo, polipeptìdeo isolado, anticorpo monoclonal, ou fragmento de ligação do antìgeno do mesmo, vetor de expressão, célula hospedeira, medicamento composição farmacêutica, e, utilização de um polipeptìdio isolado
IL165776A0 (en) Methods and compositions for modulating and detecting wisp activity
CY1109378T1 (el) Fas πεπτιδια και αντισωματα για ρυθμιση αποπτωσης
EP1593691A4 (en) PROCESS OF OBTAINING HUMAN MONOCLONAL ANTIBODIES FOR INHIBITING THE DISTRACTION OF CANCER CELLS
DE60120507D1 (de) Menschliches leucinereiche wiederholungen enthaltendes protein, vorwiegend im dünndarm exprimiert, hlrrsi1